NCT02132754View on ClinicalTrials.gov

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Solid Tumor
Interventions
BIOLOGICAL

MK-4166

BIOLOGICAL

Pembrolizumab

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02132754 - Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | Biotech Hunter | Biotech Hunter